Expression of β-catenin, GLUT3, and HK1 in hepatoblastoma and their associations with cisplatin-based chemotherapy response and prognosis
Objective To examine the associations of β-catenin, GLUT3, and HK1 expression with response to cisplatin-based chemotherapy and event-free survival (EFS) in hepatoblastoma. Methods This retrospective study included 60 children. Pretreatment expression was assessed by immunohistochemistry, and regression models were used to examine associations with treatment response and EFS. Paired pre- and postchemotherapy specimens from 24 patients were compared, and transcript-level correlations were examined in 48 publicly available hepatoblastoma samples. Results Nineteen patients had a poor response, and 42 experienced an EFS event. Abnormal/high expression of the three markers and a high combined score were associated with lower objective response rates, but none of these associations remained statistically significant after adjustment for PRETEXT stage and distant metastasis. In sensitivity models adjusted for CHIC-HS risk, the associations for GLUT3 and the combined score were statistically significant. Abnormal β-catenin expression, high GLUT3 expression, and a high combined score were associated with shorter EFS in both adjusted models; hazard ratios in the primary models were 4.26, 2.41, and 2.37, respectively. HK1 was not significantly associated with EFS. In paired specimens, the proportion of cells with nuclear β-catenin positivity and the GLUT3 and HK1 H-scores increased after chemotherapy (all P < 0.001 ). SLC2A3 and HK1 transcript levels were positively correlated, whereas CTNNB1 transcript levels were not significantly correlated with either. Conclusion Abnormal β-catenin expression, high GLUT3 expression, and a high combined score were associated with shorter EFS and may warrant further evaluation as markers for prognostic risk assessment in hepatoblastoma.
Authors
- Lingyan Wang
- Jinyuan Mei
- Yonghui Yang
- Xiuping Jia
- Yaguang Jiao
- Xinyu Wu
- Meng Wang
- Lili Zhang
- Shangjing Gong
- Li Zhang
- Jianwei Zhang
- Zehao Liu
Institutions
- Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fonc.2026.1982989
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00